Cargando…
Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, an...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880058/ https://www.ncbi.nlm.nih.gov/pubmed/36713426 http://dx.doi.org/10.3389/fimmu.2022.987231 |
_version_ | 1784878830187446272 |
---|---|
author | Pedraza-Sánchez, Sigifredo Cruz-González, Adrián Palmeros-Rojas, Oscar Gálvez-Romero, José Luis Bellanti, Joseph A. Torres, Martha |
author_facet | Pedraza-Sánchez, Sigifredo Cruz-González, Adrián Palmeros-Rojas, Oscar Gálvez-Romero, José Luis Bellanti, Joseph A. Torres, Martha |
author_sort | Pedraza-Sánchez, Sigifredo |
collection | PubMed |
description | Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage. |
format | Online Article Text |
id | pubmed-9880058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98800582023-01-28 Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance Pedraza-Sánchez, Sigifredo Cruz-González, Adrián Palmeros-Rojas, Oscar Gálvez-Romero, José Luis Bellanti, Joseph A. Torres, Martha Front Immunol Immunology Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9880058/ /pubmed/36713426 http://dx.doi.org/10.3389/fimmu.2022.987231 Text en Copyright © 2023 Pedraza-Sánchez, Cruz-González, Palmeros-Rojas, Gálvez-Romero, Bellanti and Torres https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Pedraza-Sánchez, Sigifredo Cruz-González, Adrián Palmeros-Rojas, Oscar Gálvez-Romero, José Luis Bellanti, Joseph A. Torres, Martha Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance |
title | Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance |
title_full | Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance |
title_fullStr | Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance |
title_full_unstemmed | Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance |
title_short | Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance |
title_sort | polyvalent human immunoglobulin for infectious diseases: potential to circumvent antimicrobial resistance |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880058/ https://www.ncbi.nlm.nih.gov/pubmed/36713426 http://dx.doi.org/10.3389/fimmu.2022.987231 |
work_keys_str_mv | AT pedrazasanchezsigifredo polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance AT cruzgonzalezadrian polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance AT palmerosrojasoscar polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance AT galvezromerojoseluis polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance AT bellantijosepha polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance AT torresmartha polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance |